Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Authors
Keywords
-
Journal
Therapeutic Advances in Musculoskeletal Disease
Volume 9, Issue 11, Pages 277-294
Publisher
SAGE Publications
Online
2017-12-12
DOI
10.1177/1759720x17735756
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation
- (2017) Jérôme C. Martin et al. JOURNAL OF IMMUNOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets
- (2016) Giulia Merlo et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition
- (2016) P. Skendros et al. BRITISH JOURNAL OF DERMATOLOGY
- Bone remodeling in psoriasis and psoriatic arthritis
- (2016) Ananta Paine et al. CURRENT OPINION IN RHEUMATOLOGY
- Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis
- (2016) Wei-Chih Ko et al. Dermatologica Sinica
- A revolutionary therapeutic approach for psoriasis: bispecific biological agents
- (2016) T. Torres et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis
- (2016) Junfeng Zhang et al. JOURNAL OF IMMUNOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease
- (2016) Dorota Purzycka-Bohdan et al. PLoS One
- Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis?
- (2016) Aleksandra Lesiak et al. Postepy Dermatologii i Alergologii
- Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)
- (2015) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab
- (2015) B. Mansouri et al. BRITISH JOURNAL OF DERMATOLOGY
- Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab
- (2015) B. Mansouri et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Serum IL-33 levels are increased in patients with psoriasis
- (2015) A. Mitsui et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
- (2015) Ulrich Mrowietz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
- (2015) Ian Landells et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Role of IL-38 and Its Related Cytokines in Inflammation
- (2015) Xianli Yuan et al. MEDIATORS OF INFLAMMATION
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atherosclerosis in psoriatic disease: latest evidence and clinical implications
- (2015) Lihi Eder et al. Therapeutic Advances in Musculoskeletal Disease
- First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis
- (2015) Alice B. Gottlieb et al. PLoS One
- A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab
- (2014) P. Jayasekera et al. BRITISH JOURNAL OF DERMATOLOGY
- Partial clinical response to anakinra in severe palmoplantar pustular psoriasis
- (2014) M. Tauber et al. BRITISH JOURNAL OF DERMATOLOGY
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
- (2014) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy of tocilizumab in a patient with refractory psoriatic arthritis
- (2014) Luisa Costa et al. CLINICAL RHEUMATOLOGY
- The economic burden of psoriatic diseases in Taiwan
- (2014) Kuan-Chen Chen et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines
- (2014) S. Sharma et al. JOURNAL OF IMMUNOLOGY
- IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis
- (2014) Ellen Witte et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab
- (2013) A Gedebjerg et al. ACTA DERMATO-VENEREOLOGICA
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?
- (2013) M. Tauber et al. BRITISH JOURNAL OF DERMATOLOGY
- Serum Cytokines Correlated with The Disease Severity of Generalized Pustular Psoriasis
- (2013) Masaaki Yamamoto et al. DISEASE MARKERS
- Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice
- (2013) Snehlata Kumari et al. IMMUNITY
- Psoriasis onset with tocilizumab
- (2013) Anne Grasland et al. JOINT BONE SPINE
- Therapeutic opportunities of the IL-22–IL-22R1 system
- (2013) Robert Sabat et al. NATURE REVIEWS DRUG DISCOVERY
- Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis
- (2013) Tej Pratap Singh et al. PLoS One
- Successful use of tocilizumab in a patient with psoriatic arthritis
- (2013) M. Hughes et al. RHEUMATOLOGY
- Interleukin 35: A Key Mediator of Suppression and the Propagation of Infectious Tolerance
- (2013) Brian M. Olson et al. Frontiers in Immunology
- Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis
- (2012) Z. He et al. BRITISH JOURNAL OF DERMATOLOGY
- Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24
- (2012) F. Wang et al. BRITISH JOURNAL OF DERMATOLOGY
- T helper type 17 in psoriasis: From basic immunology to clinical practice
- (2012) Hsien-Yi Chiu et al. Dermatologica Sinica
- IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation
- (2012) Anna Balato et al. EXPERIMENTAL DERMATOLOGY
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis
- (2012) Javier Rueda-Gotor et al. JOINT BONE SPINE
- Tumor Necrosis Factor-associated Palmoplantar Pustular Psoriasis Treated with Interleukin 6 Blocker
- (2012) S. YOUNIS et al. JOURNAL OF RHEUMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque Psoriasis
- (2012) William R. Swindell et al. PLoS One
- IL-35 Is a Novel Responsive Anti-inflammatory Cytokine — A New System of Categorizing Anti-inflammatory Cytokines
- (2012) Xinyuan Li et al. PLoS One
- Interleukin-18 expression and the response to treatment in patients with psoriasis
- (2011) Hanaa Rasmy Mohamed Attia et al. Archives of Medical Science
- Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) A.B. Gottlieb et al. BRITISH JOURNAL OF DERMATOLOGY
- Interleukin (IL)-17 versus IL-27: opposite effects on tumor necrosis factor-α-mediated chemokine production in human keratinocytes
- (2011) Susumu Fujiwara et al. EXPERIMENTAL DERMATOLOGY
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
- (2011) Kenneth B. Gordon et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
- (2011) Slaheddine Marrakchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
- (2011) Kristian Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased IL-23 Expression in Palmoplantar Psoriasis and Hyperkeratotic Hand Dermatitis
- (2010) Joseph V. Lillis et al. ARCHIVES OF DERMATOLOGY
- Long-term control of refractory Schnitzler syndrome with anakinra: a case report
- (2010) Hsien-Yi Chiu et al. Dermatologica Sinica
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible Roles of IL-27 in the Pathogenesis of Psoriasis
- (2009) Sayaka Shibata et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not
- (2009) Kerstin Wolk et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis
- (2009) Roberta Caruso et al. NATURE MEDICINE
- IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells
- (2009) W. Elyaman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra
- (2008) M.A. González-López et al. BRITISH JOURNAL OF DERMATOLOGY
- Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells
- (2008) Franca Gerosa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- IL-21 and TGF-β are required for differentiation of human TH17 cells
- (2008) Li Yang et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More